Compare SPEG & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPEG | GNLX |
|---|---|---|
| Founded | 2024 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9M | 133.0M |
| IPO Year | N/A | 2022 |
| Metric | SPEG | GNLX |
|---|---|---|
| Price | $10.30 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 42.5K | ★ 199.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $2.29 |
| 52 Week High | $11.03 | $8.54 |
| Indicator | SPEG | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | N/A |
| Support Level | $10.26 | N/A |
| Resistance Level | $10.35 | N/A |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 88.89 | 0.00 |
Silver Pegasus Acquisition Corp is a blank check company.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.